The first-phase clinical effect is significant, and the anti-new crown new drug developers explain the experimental details in detail

　　International war "epidemic" operation

　　◎Our reporter Hu Dingkun

　　Recently, some media reported that Israel has developed a new type of drug that can cure patients with severe new coronary pneumonia in just a few days by inhaling from the nasal cavity.

Of the 30 critically ill volunteers who participated in the first phase of clinical trials, 29 of them recovered after 5 days of treatment.

On February 17, Nadir Alber, the inventor of the drug and a professor at Israel’s Izirov Hospital, unveiled the mystery of the drug to multinational media including Science and Technology Daily through a video conference.

　　Albert said that the drug is a combination of CD24 protein and exosomes, so it was named EXO-CD24.

CD24 can not only bind to the endogenous molecules (DAMPs) released by the body's cell death, prevent DAMPs from causing further immune responses, and at the same time block the Siglec-10 receptors of immune cells, both of which regulate the immune system.

Exosomes are small lipid vesicles, which can shuttle proteins, RNA and other substances between cells, and they are mainly used as transport vehicles for CD24.

The "strong combination" of the two can effectively suppress the "immune storm" common to patients with severe new coronary disease.

　　The so-called "immune storm" is that the immune system of patients with new coronary pneumonia is overactivated and out of control. While eliminating the invading virus, it causes serious damage to their own tissues and organs. This is an important cause of death from new coronary pneumonia.

Therefore, the role of EXO-CD24 is not to eliminate the virus directly, but to allow the immune system to safely remove the virus by containing the immune storm.

　　A reporter from the Science and Technology Daily learned from the video conference that in September 2020, the Israeli Ministry of Health approved EXO-CD24 to start clinical trials.

The first 30 patients were all severely ill, ranging in age from 33 to 77 years old, with an average age of 58 years old, and one third of them were women.

The above-mentioned patients were divided into 3 groups according to the dosage of the drugs used, including 5 in the low-dose group, 5 in the middle-dose (5 times the low dose) group, and 20 in the high-dose (10 times the low dose) group.

Results Except for one person who stopped participating in the trial because of being transferred to the intensive care unit, the remaining 29 people were cured after 5 days of treatment, and none of them had serious side effects due to the drugs.

　　According to Albert, there is currently a group of 5 people with the highest dose (100 times the low dose) is still in the trial process, and the results are yet to be counted.

　　According to the condition information published by Albert, most of the recovered patients had their blood oxygen concentration dropped to 90 to 92 before treatment with EXO-CD24, and the respiratory rate was close to 30, which was hypoxic. The reactive protein level was mostly over 100 and the highest reached 400. Above, it shows serious infection.

After the treatment, the patient's blood oxygen concentration increased significantly, and more than 20 people reached 95 or more, the respiratory frequency all fell below 25, the level of reactive protein generally decreased, and the hypoxia and infection conditions were significantly improved.

　　Albert said that, compared to the traditional treatment of using steroids to suppress immune storms, EXO-CD24 is directly inhaled through the trachea to the heart of immune storms-the "lungs", using exosomal technology for low-dose local administration, which is safer High, no adverse reactions and significant effects.

At the same time, it is easy to produce and low in cost.

In addition, the drug may be used to treat other acute respiratory distress syndrome, asthma, allergic reactions, autoimmune system diseases and other problems.

　　It is reported that Israeli researchers will carry out further tests on EXO-CD24.

　　On February 8, Israeli Prime Minister Netanyahu said in a meeting with Albert and others who participated in the EXO-CD24 study: "(EXO-CD24), if successful, will have great and global significance."